Sam Chun Dang Pharm KRX:000250KOSDAQ
삼천당제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Sam Chun Dang Pharm reported revenue of ₩70.7bn, up 24.3% year on year, and operating profit of ₩3.4bn. Sam Chun Dang Pharm (삼천당제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Turnaround Screener
Sam Chun Dang Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩70.7bn | +24.3% | ₩3.4bn | ₩6.2bn |
| Q1 2026 | ₩64.9bn | +28.2% | ₩5.4bn | ₩6.9bn |
| Q4 2025 derived | ₩66.3bn | +20.1% | ₩5.4bn | ₩7.9bn |
| Q3 2025 | ₩58.0bn | +10.8% | ₩3.4bn | ₩4.5bn |
| Q2 2025 | ₩56.9bn | +3.7% | −₩1.1bn | −₩1.6bn |
| Q1 2025 | ₩50.6bn | +4.5% | ₩688m | ₩1.3bn |
| Q4 2024 derived | ₩55.2bn | +5.1% | −₩545m | −₩8.9bn |
| Q3 2024 | ₩52.4bn | +8.1% | −₩814m | −₩285m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Sam Chun Dang Pharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Sam Chun Dang Pharm news Korean headlines
No articles yet.